Welcome to our dedicated page for ASP Isotopes news (Ticker: ASPI), a resource for investors and traders seeking the latest updates and insights on ASP Isotopes stock.
ASP Isotopes Inc. develops isotope enrichment technologies and related critical-materials businesses for nuclear medicine, next-generation semiconductors, nuclear energy and helium markets. Company news commonly covers its Aerodynamic Separation Process and Quantum Enrichment platforms, enrichment facilities in Pretoria, South Africa, and target isotopes such as Silicon-28, Carbon-14 and Ytterbium-176.
Recurring updates also address PET Labs radiopharmaceutical operations, Quantum Leap Energy nuclear fuel-cycle initiatives, lithium laser enrichment research, Renergen and the Virginia Gas Project, material agreements, governance matters, capital-structure disclosures, and operating and financial results.
ASP Isotopes (NASDAQ: ASPI) said a UK subsidiary of Quantum Leap Energy has begun a strategic collaboration with the University of Bristol to design a lithium laser enrichment research facility. The University will lead a site-agnostic feasibility and design study in an estimated four-month initial phase, including safety reviews and RIBA Stage 4 technical design.
Subject to a positive feasibility assessment, parties intend to proceed to construction at a suitable Bristol site; work was developed in consultation with UK regulators including the Department for Energy Security and Net Zero and the Office for Nuclear Regulation.
ASP Isotopes (NASDAQ: ASPI) completed drilling for Phase 1 of the Renergen Helium Project about four months ahead of schedule on March 23, 2026. New wells delivered gas flows up to 16x prior wells and the project has reached Phase 1 nameplate flow, reducing execution risk.
ASP expects Phase 1 to produce 2,500 GJ/day LNG and 58 MCF/day helium, and Phase 2 to target 34,000 GJ/day LNG and 895 MCF/day helium after a 44-month build.
ASP Isotopes (NASDAQ: ASPI) announced that CEO Paul Mann will appear in a fireside chat at Canaccord Genuity’s 2nd Annual CG Virtual Sustainability Summit on Thursday, March 12, 2026 at 3:20 p.m. ET.
A live audio webcast will be available in the Company’s Investors section and a replay posted within 48 hours after the event.
ASP Isotopes (NASDAQ: ASPI) subsidiary Quantum Leap Energy entered a non-binding MOU with a large U.S. energy company to evaluate support for U.S.-based advanced nuclear fuel facilities. The facilities are planned to produce HALEU, LEU+, and provide conversion/deconversion services to strengthen the domestic supply chain.
QLE said the MOU outlines potential financial support terms tied to definitive supply agreements and anticipates technical diligence and pathways toward long-term commercial collaboration.
ASP Isotopes (NASDAQ: ASPI) announced that Quantum Leap Energy appointed Dr. Nate Salpeter as Chief Technology Officer on March 5, 2026. Dr. Salpeter brings over 15 years of experience building computational and experimental programs at TerraPower, Kairos Power, and other organizations.
He will focus on optimizing in-licensed and proprietary technologies, standing up computational and experimental frameworks, implementing rapid learning cycles, and leading disciplined de-risking to advance QLE's commercialization objectives.
ASP Isotopes (NASDAQ: ASPI) announced that a South African subsidiary of Quantum Leap Energy executed a Services Contract on Feb 20, 2026 with the South African Nuclear Energy Corporation (Necsa) to advance research, design and potential commercial production of HALEU at Necsa's Pelindaba site.
The agreement provides QLE SA access to facilities, infrastructure and services for siting, design, construction, commissioning and operation, establishes a Joint Coordination Committee, and is subject to Necsa site rules and required National Nuclear Regulator approvals.
ASP Isotopes (NASDAQ: ASPI) said on Feb 19, 2026 that its wholly owned subsidiary Quantum Leap Energy (QLE) formed a Strategic Advisory Board and appointed Mary Lou Dunzik-Gougar and Kevin Kramer as initial members.
QLE will advise on nuclear fuel cycle gaps while developing proprietary isotope enrichment technologies including the ASP aerodynamic process and laser-based Quantum Enrichment (QE) to target cost, safety, and supply-chain improvements for fission and fusion fuel applications.
ASP Isotopes (NASDAQ: ASPI) said its wholly owned subsidiary Quantum Leap Energy will establish global headquarters in Austin, Texas, expanding QLE’s U.S. presence and operational plans. QLE plans a significant Texas footprint and to advance a joint venture with Fermi America tied to HALEU enrichment and isotope production.
QLE and ASPI plan facilities affiliated with Fermi America’s Amarillo hypergrid campus, aligning with DOE estimates of rising HALEU demand through 2035–2050.
ASP Isotopes (NASDAQ: ASPI) provided a production update on the Renergen Helium Project after completing its January 6, 2026 acquisition of Renergen. Since operations restarted in April 2025, management reports ~60% higher gas throughput, 15 gas intersections (~80% drilling success), ~60% of Phase 1 LNG contracted, and ongoing plant commissioning aimed at positive operational cash flow before end-2026.
Upgrades include a new compressor station, cold-box modifications, CO2 scrubber, gas-gathering >70% complete, and additional drilling and evaluation of a newly identified shallow sandstone reservoir.
ASP Isotopes (Nasdaq: ASPI) closed its acquisition of Renergen on January 7, 2026, creating a combined company focused on isotope production and liquid helium supply for semiconductors, quantum computing and clean energy.
Key financing includes a prior $40 million U.S. DFC finance agreement and expected debt facilities totaling $750 million (a $500 million senior DFC facility and a $250 million Standard Bank facility) to expand helium production at the Virginia Gas project. The company approved 700,000 inducement shares for two Renergen executives with four-year vesting. A Virtual Investor Update is planned for late January.